BioPharma, Pharma Merck Drug for Heart and Lung Disorder Wins a First-in-Class FDA Approval By Frank Vinluan
BioPharma, Devices & Diagnostics Rigorous Data Are Key to Convince Payers, Investors in the World of Digital Therapeutics By Frank Vinluan
Health Tech Peterson Center on Healthcare Launches $50M Institute To Assess Digital Health Solutions By Marissa Plescia
BioPharma, Pharma FDA Approval of Eisai Alzheimer’s Drug Bears Imprint of Aduhelm Review By Frank Vinluan
BioPharma, Pharma CSL’s Gene Therapy Approval Marks First for Hemophilia B and New High in Pricing By Frank Vinluan
BioPharma, Pharma Cost of Amylyx ALS drug revives pricing debate for new meds in rare diseases By Frank Vinluan
MedCity Influencers, Opinion Aduhelm’s loss is a win for value-based drug pricing By Girisha Fernando
BioPharma, Pharma Potential blockbuster BMS cardio drug gets FDA nod, first in rare heart disease By Frank Vinluan
Artificial Intelligence, BioPharma Aetion acquires Replica Analytics to bring aboard synthetic data capabilities By Frank Vinluan
BioPharma, Pharma FDA nod for Novartis sets up cholesterol drug showdown with Amgen, Regeneron By Frank Vinluan
BioPharma, Pharma Biogen slashes price of Alzheimer’s drug by half as CMS coverage decision looms By Frank Vinluan
BioPharma, Legal Drug price hikes without new evidence upped spending by $1.2B, ICER says By Khadijah M. Silver
MedCity Influencers, Health Tech, Health Services How the value of innovation will be redefined in 2021 By
BioPharma Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients By Alaric DeArment
